Glyshield G2 Tablet SR is a sustained-release oral hypoglycemic agent combining Glimepiride (2mg) and Metformin (500mg), indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class drug, stimulates pancreatic beta cells to increase insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, enhancing glucose uptake by muscle tissues. The sustained-release formulation ensures a gradual release of active ingredients, promoting stable glycemic control and minimizing gastrointestinal side effects commonly associated with immediate-release metformin. Glyshield G2 is prescribed as part of a comprehensive diabetes management plan that includes diet, exercise, and lifestyle modifications. It is particularly beneficial for patients inadequately controlled on monotherapy or those requiring combination therapy to achieve target glycemic levels. Caution is advised in patients with renal impairment, hepatic dysfunction, or conditions predisposing to lactic acidosis. Regular monitoring of blood glucose, renal function, and liver enzymes is recommended during therapy. Glyshield G2 should be used under medical supervision, with dose adjustments based on therapeutic response and tolerability. This combination therapy offers an effective approach to improving glycemic control in type 2 diabetes patients.